Mahesh C. Sharma
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mahesh C. Sharma has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
George P. Tuszynski
Department of Neuroscience, Temple University School of Medicine, Philadelphia, PA 19140, USA
6 shared publicationsMeena R. Sharma
University of Pennsylvania, Philadelphia, PA 19104, USA
6 shared publicationsMeena Sharma
University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
5 shared publicationsBernard H. Shapiro
3 shared publicationsVicki L. Rothman
Temple University School of Medicine
3 shared publicationsMarc R. Blackman
Research Service, Veterans Affairs Medical Center, Washington, DC 20422, USA; Department of Biochemistry and Molecular Medicine, George Washington University, Washington, DC, USA; Department of Medicine, George Washington University, Washington, DC, USA
2 shared publications
Latest Publications
- 1 October 2020
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 116, 104523
Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth
- 1 October 2020
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 116, 104523
Important role of annexin A2 (ANXA2) in new blood vessel development in vivo and human triple negative breast cancer (TNBC) growth
- 31 October 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (9) , 2074-2081
Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers
ANX A2 is an important member of annexin family of proteins expressed on surface of endothelial cells (ECs), macrophages, mononuclear cells and various types of cancer cells. It exhibits high affinity binding for calcium (Ca++) and phospholipids. ANX A2 plays an important role in many biological processes such as endocytosis, exocytosis, autophagy, cell–cell communications and biochemical activation of plasminogen. On the cell surface ANX A2 organizes the assembly of plasminogen (PLG) and tissue plasminogen activator (tPA) for efficient conversion of PLG to plasmin, a serine protease. Proteolytic activity of plasmin is required for activation of inactive pro‐metalloproteases (pro‐MMPs) and latent growth factors for their biological actions. These activation steps are critical for degradation of extracellular matrix (ECM) and basement proteins (BM) for cancer cell invasion and metastasis. Increased expression of ANX A2 protein/gene has been correlated with invasion and metastasis in a variety of human cancers. Moreover, clinical studies have positively correlated ANX A2 protein expression with aggressive cancers and with resistance to anticancer drugs, shorter disease‐free survival (DFS), and worse overall survival (OS). The mechanism(s) by which ANX A2 regulates cancer invasion and metastasis are beginning to emerge. Investigators used various technologies to target ANX A2 in preclinical model of human cancers and demonstrated exciting results. In this review article, we analyzed existing literature concurrent with our own findings and provided a critical overview of ANX A2‐dependent mechanism(s) of cancer invasion and metastasis.
- 31 October 2018
- Published by Wiley in International Journal of Cancer
- Vol. 144 (9) , 2074-2081
Annexin A2 (ANX A2): An emerging biomarker and potential therapeutic target for aggressive cancers
ANX A2 is an important member of annexin family of proteins expressed on surface of endothelial cells (ECs), macrophages, mononuclear cells and various types of cancer cells. It exhibits high affinity binding for calcium (Ca++) and phospholipids. ANX A2 plays an important role in many biological processes such as endocytosis, exocytosis, autophagy, cell–cell communications and biochemical activation of plasminogen. On the cell surface ANX A2 organizes the assembly of plasminogen (PLG) and tissue plasminogen activator (tPA) for efficient conversion of PLG to plasmin, a serine protease. Proteolytic activity of plasmin is required for activation of inactive pro‐metalloproteases (pro‐MMPs) and latent growth factors for their biological actions. These activation steps are critical for degradation of extracellular matrix (ECM) and basement proteins (BM) for cancer cell invasion and metastasis. Increased expression of ANX A2 protein/gene has been correlated with invasion and metastasis in a variety of human cancers. Moreover, clinical studies have positively correlated ANX A2 protein expression with aggressive cancers and with resistance to anticancer drugs, shorter disease‐free survival (DFS), and worse overall survival (OS). The mechanism(s) by which ANX A2 regulates cancer invasion and metastasis are beginning to emerge. Investigators used various technologies to target ANX A2 in preclinical model of human cancers and demonstrated exciting results. In this review article, we analyzed existing literature concurrent with our own findings and provided a critical overview of ANX A2‐dependent mechanism(s) of cancer invasion and metastasis.
- 1 April 2016
- Published by Elsevier in Cancer Letters
- Vol. 373 (1) , 27-35
Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer
- 1 April 2016
- Published by Elsevier in Cancer Letters
- Vol. 373 (1) , 27-35
Long-term efficacy and downstream mechanism of anti-annexinA2 monoclonal antibody (anti-ANX A2 mAb) in a pre-clinical model of aggressive human breast cancer
- 1 February 2012
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 92 (1) , 175-184
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model
- 1 February 2012
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 92 (1) , 175-184
Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model
- 1 April 2010
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 88 (2) , 278-286
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation
- 1 April 2010
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 88 (2) , 278-286
Breast cancer cell surface annexin II induces cell migration and neoangiogenesis via tPA dependent plasmin generation
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 15 (17) , 1949-1955
Inflammation, Microenvironment, and the Immune System in Cancer Progression
Since Virchow first proposed in 1863 that tumors could originate from sites of chronic inflammation, it has been well established that chronic inflammation both contributes to cancer progression and predisposes tissue to various types of cancer. Experimental, clinical, and epidemiological studies have all demonstrated the strong association between chronic inflammation and cancer, and many studies have correlated the prolonged presence of the inflammatory milieu with an increased risk for developing cancer. Proinflammatory cytokines, chemokines and adhesion molecules, which regulate the sequential recruitment of leukocytes, are frequently observed in tumor microenvironment. These early desmoplastic changes could stimulate fibroblasts and endothelial cell division and produce components for tissue remodeling and neovascularization, ultimately promoting neoplastic processes. In this review article we overview the current understanding of the role of chronic inflammation in neoangiogenesis, tumor initiation, promotion, and progression.
- 1 June 2009
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 15 (17) , 1949-1955
Inflammation, Microenvironment, and the Immune System in Cancer Progression
Since Virchow first proposed in 1863 that tumors could originate from sites of chronic inflammation, it has been well established that chronic inflammation both contributes to cancer progression and predisposes tissue to various types of cancer. Experimental, clinical, and epidemiological studies have all demonstrated the strong association between chronic inflammation and cancer, and many studies have correlated the prolonged presence of the inflammatory milieu with an increased risk for developing cancer. Proinflammatory cytokines, chemokines and adhesion molecules, which regulate the sequential recruitment of leukocytes, are frequently observed in tumor microenvironment. These early desmoplastic changes could stimulate fibroblasts and endothelial cell division and produce components for tissue remodeling and neovascularization, ultimately promoting neoplastic processes. In this review article we overview the current understanding of the role of chronic inflammation in neoangiogenesis, tumor initiation, promotion, and progression.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (35) , 3568-3575
The Role of Annexin II in Angiogenesis and Tumor Progression: A Potential Therapeutic Target
It is well established that human tumors overproduce plasmin a serine protease that is known to promote angiogenesis, tumor growth and metastasis. However, the mechanism by which endothelial or tumor cells regulate the proteolytic activity of plasmin is not well understood. Cell surface receptors regulate activation of plasminogen to plasmin and its proteolytic activity. Annexin II is one of the well studied receptors for plasminogen and tPA, which binds to plasminogen and converts it to plasmin. Plasmin is a highly reactive enzyme which is physiologically involved in fibrinolysis. Since the proteolytic activity of plasmin is very tightly regulated, uncontrolled production of plasmin can degrade extracelluar matrix (ECM) and basement membrane (BM) of the surrounding blood vessels. Thus plasmin plays an important role in neoangiogenesis and cancer invasion and metastasis. Therefore, the receptor which regulates plasmin generation may be an attractive target for the development of anti-cancer/anti-metastatic agents. Angiostatin (AS), internal fragment of plasminogen, has been reported to inhibit human tumor growth and metastasis. We have shown that AS binds to endothelial/cancer cell surface annexin II with high affinity and interferes with plasmin generation suggesting that the role of plasmin/plasminogen system may be more complex than we previously thought. In this review we provide a comprehensive analysis of the literature in context of the role of annexin II in angiogenesis, tumor progression and metastasis. Compelling evidence from the literature and our own findings suggest that annexin II may be a potential target for the development of effective therapeutic strategies for the treatment of cancer and its induced metastasis.
- 1 December 2007
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 13 (35) , 3568-3575
The Role of Annexin II in Angiogenesis and Tumor Progression: A Potential Therapeutic Target
It is well established that human tumors overproduce plasmin a serine protease that is known to promote angiogenesis, tumor growth and metastasis. However, the mechanism by which endothelial or tumor cells regulate the proteolytic activity of plasmin is not well understood. Cell surface receptors regulate activation of plasminogen to plasmin and its proteolytic activity. Annexin II is one of the well studied receptors for plasminogen and tPA, which binds to plasminogen and converts it to plasmin. Plasmin is a highly reactive enzyme which is physiologically involved in fibrinolysis. Since the proteolytic activity of plasmin is very tightly regulated, uncontrolled production of plasmin can degrade extracelluar matrix (ECM) and basement membrane (BM) of the surrounding blood vessels. Thus plasmin plays an important role in neoangiogenesis and cancer invasion and metastasis. Therefore, the receptor which regulates plasmin generation may be an attractive target for the development of anti-cancer/anti-metastatic agents. Angiostatin (AS), internal fragment of plasminogen, has been reported to inhibit human tumor growth and metastasis. We have shown that AS binds to endothelial/cancer cell surface annexin II with high affinity and interferes with plasmin generation suggesting that the role of plasmin/plasminogen system may be more complex than we previously thought. In this review we provide a comprehensive analysis of the literature in context of the role of annexin II in angiogenesis, tumor progression and metastasis. Compelling evidence from the literature and our own findings suggest that annexin II may be a potential target for the development of effective therapeutic strategies for the treatment of cancer and its induced metastasis.
- 1 February 2007
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 82 (1) , 25-32
Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5
- 1 February 2007
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 82 (1) , 25-32
Roscovitine regulates invasive breast cancer cell (MDA-MB231) proliferation and survival through cell cycle regulatory protein cdk5
- 1 October 2006
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 81 (2) , 146-156
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression
- 1 October 2006
- Published by Elsevier in Experimental and Molecular Pathology
- Vol. 81 (2) , 146-156
Angiogenesis-associated protein annexin II in breast cancer: Selective expression in invasive breast cancer and contribution to tumor invasion and progression